Compare PNTG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | EVO |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 934.1M |
| IPO Year | 2019 | N/A |
| Metric | PNTG | EVO |
|---|---|---|
| Price | $35.90 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $37.00 | $7.00 |
| AVG Volume (30 Days) | ★ 170.7K | 95.4K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $947,705,000.00 | N/A |
| Revenue This Year | $24.72 | $1.37 |
| Revenue Next Year | $7.61 | $10.05 |
| P/E Ratio | $146.33 | ★ N/A |
| Revenue Growth | ★ 36.31 | N/A |
| 52 Week Low | $21.74 | $2.31 |
| 52 Week High | $35.25 | $4.80 |
| Indicator | PNTG | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 75.18 | 52.19 |
| Support Level | $28.05 | $2.88 |
| Resistance Level | N/A | $3.78 |
| Average True Range (ATR) | 1.47 | 0.12 |
| MACD | 0.63 | -0.01 |
| Stochastic Oscillator | 83.05 | 33.33 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.